MARKERS COLLAGENOPATHY AND SCLEROSIS IN THE DIAGNOSIS OF THE PROGRESSION OF REFLUX NEPHROPATHY IN CHILDREN

THE AIM. To reveal the informative indicators for the prediction of progression of reflux nephropathy in children with vesicoureteral reflux based on the study of the urinary excretion of markers of sclerosis (transforming growth factor-β₁), angiotensin II, procalcitonin, β₂-microglobulin) and collagenopathy (peptidoglycans and free hydroxyproline). PATIENTS AND METHODS: the study group included 71 (52 girls) the patient at the age of 5.69±0.44 years with vesicoureteral reflux (VUR). Based on the results of DMSA-scintigraphy, all children were divided into 2 groups: the control group 9 children with VUR without foci of sclerosis and a study group included 62 patients with different degrees of reflux nephropathy (RN). The control group consisted of 20 healthy children at the age of 6.24 ± 0.31 years. In all children investigated the urinary excretion of AngII, TGF-β₁, PCT, β₂-MG, PSH and FH and counted it to the level of creatinine in the urine. RESULTS. Urinary levels of AngII, TGF-β₁, PCT, β₂-MG, PSH, and FH was significantly higher in groups of children with RN when compared with the control group. The highest level AngII, TGF-β₁, PCT was defined in the main group (p<0.05). Patients with a severe degree of RN, the ><0.05). Patients with a severe degree of RN, thelevel of AngII, TGF-β₁, PCT in urine was higher when compared with the control group and the group of children without foci of sclerosis (p<0.05). CONCLUSION. Installed direct correlation between the level of excretion AngII, TGF-β₁, PCT and the severity of RN in patients with VUR indicates the feasibility and prospects of their inclusion as diagnostic markers predict the severity of reflux nephropathy.

1. Anichkova IV, Papayan AV. Reflyuks-nefropatiya. Klinicheskaya nefrologiya detskogo vozrasta SPb.: Levsha. Sankt-peterburg, 2008; 452–457

2. Papayan AV., Savenkova ND. Klinicheskaya nefrologiya detskogo vozrasta SPb.: Levsha. Sankt-peterburg, 2008: 600

3. Tej K. Mattoo. Vesicoureteral Reflux and Reflux Nephropa-thy. Adv Chronic Kidney Dis 2011; 18(5): 348–354

4. Daminova MA. Hronicheskaya bolezn pochek u detey: etiologiya, klassifikatsiya i faktoryi progressirovaniya. Vestnik sovremennoy klinicheskoy meditsinyi 2016;9(2):36–41

5. Giovanni M, Kjell T, Hewitt I. Febrile Urinary Tract Infections in Children. New Engl J of Medicine 2011; 365:239–250

6. Machehina LYu. Sovremennyie vzglyadyi na patogeneticheskie mehanizmyi, techenie, prognoz i metodyi lecheniya reflyuks-nefropatii. Avtor. diss. na sosk. uch. step. kand. med. nauk, Moskva, 2010: 38

7. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Annual report. 2010. The EMMES Corporation, Rockville, MD.

8. Salo J, Ikäheimo R, Tapiainen T. Childhood urinary tract infections as a cause of chronic kidney disease. Pediatrics 2011;128(5):840

9. Massanyi EZ, Preece J, Gupta A et al. Utility of screening ultrasound after first febrile UTI among patients with clinically significant vesicoureteral reflux. Urology 2013; 82(4):905–910

10. Liang, X.L. Beyond Early Diagnosis: Prognostic Biomarkers for Monitoring Acute Kidney Injury: X.-L. Liang, W. Shi. Hong Kong J. Nephrol. 2010; 12(2):45–49

11. Zorin IV, Vyalkova AA. Prognozirovanie progressirovaniya tubulo-interstitsialnogo porazheniya pochek u detey s reflyuksnefropatiey. Nefrologiya 2015;19(3): 65–71

12. Chichuga EM, Nastausheva TL, Zvyagina TG. Markeryi hronicheskoy bolezni pochek u detey s obstruktsiey mochevyih putey i puzyirnomochetochnikovyim reflyuksom. Pediatricheskaya farmakologiya 2015;12 (4): 407–413

13. Urazaeva LI, Maksudova AN. Biomarkeryi rannego povrezhdeniya pochek: Nefrologiya, prakticheskaya meditsina, innovatsionnyie tehnologii v meditsine. Redaktor 2014;1:125–130

14. Lee RS. Biomarkers for peadiatric urological disease. Curr Opin Urol 2009;19 (4): 397–401

15. Chertin B, Rolle U, Cascio S. Upregulation of angiotensin II receptors in reflux nephropathy. Pediatr Surg 2002; 37(2):251–255

16. Morales MG, Vazquez Y, Acuña MJ et al. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int J Biochem Cell Biol 2012;44(11):1993–2002

17. Fouzas S, Krikelli E, Vassilakos P et al. DMSA scan for revealing vesicoureteral reflux in young children with urinary tract infection. Pediatrics 2010;126:513–519

18. Strelkova TN. Klinicheskoe znachenie otsenki metabolitov obmena kollagena pri pielonefritah u detey. Meditsinskiy almonah: GBOU VPO «Izhevskaya gosudarstvennaya meditsinskaya akademiya» 2012; 2:(21):217

19. Lebowitz RL, Olbing H, Parkkulainen KV et al. International system of radiographic grading of vesicoureteric reflux. International Reflux Study in Children. Pediatr Radiol 1985; 15:105–109

20. Piepsz A, Colarinha P, Gordon I, Hahn K. Peadiatric Committee of the European Association of Nuclear Medicine. Guidelines for 99-mTc-DMSA scintigraphy in children. Eur J Nucl Med 2001; 28:BP37–BP41

21. Hussein A, Askar E, Elsaeid M, Schaefer F. Functional polymorphisms in transforming growth factor-beta-1 (TGFbeta-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection. Nephrol Dial Transplant 2010; 25:779–785

22. Ruiz-Ortego M, Lorenso O, Suzuki Y, Ruperes M. Proinflamatory actions of angiotensin II. Curr Opin Nephrol Hypertens 2001; 10:321–329

23. Biohimiya: uchebnik dlya vuzov pod red. E.S.Severina; 2009 (5):768

24. Sabasinsca A, Zoch-Zwierz V, Wasilevsca A, Porowski T. Laminin and transforming growth factor beta-1 in children with vesicoureteric reflux. Pediatr Nephrol 2008; 23:769–774

25. Peter J. Margetts, Catherine Hoff, Limin Liu. Transforming growth factor β-induced peritoneal fibrosis is mouse strain dependent. Oxford Journals Medicine Nephrology Dialysis Transplantation 2012; 28(8): 2015–2027

26. Mahachev VM, Korsunskiy AA, Osmanov IM, Dlin VV. Klinicheskoe znachenie opredeleniya belkov v moche dlya ranney diagnostiki reflyuks-nefropatii u detey. Nefrologiya i dializ, 2005;7(1):41–45

27. Chiou YY, Chiu NT, Chen MJ, Cheng HL. Role of beta 2-mi-croglobulinuria and microalbuminuria in pediatric febrile urinary tract infection. Acta Paediatr Taiwan 2001;42(2):84–89

28. Sali V. Importanţa diagnostică a determinării α-glicozidazei neutre şi a β2-microglobulinei în pilonefrita cronică. Arta Medică, 2007:5 (26):41–44

29. Karlen J, Linne T, Wikstad I, Aperia A. Incidence of mi-croalbuminuria in children with pyelonephritic scarring. Pediatr Nephrol 1996;10(6):705–708

30. Kaminska A, Jung A, Olszewski S. β2-microglobulinuria in children with vesico-ureteral reflux and recurrent urinary tract infections. Pol Merkuriusz Lek 2000; 8 (46):240–241

31. Kivirikko KI. Urinary excretion of hydroxyproline in health and disease. Int rev Connect Tiss Res 1970; 5:93–163

32. Phang JM, Hu CA, Valle D. Disorders of profile and hydroxyproline metabolism. In: Scriver CR, Beaudet AL, SLY ws, Vallee D. The metabolic and molecular bases of inherited disease.

33. McGraw – Hill: New York 2001:1821–1938

34. Nikfar R, Khotaee G, Ataee N, Shams S. Usefulness of procalcitonin rapid test for the diagnosis of acute pyelonephritis in children in the emergency department. Pediatrics International 2010;52(2):196–198

35. Leroy S, Gervaix A. Procaltitonin: A key marker in children with urinary tract unfection. Advances in urology 2011; 1–7

36. Zaharova I.N, Kucherova VV. Rol prokaltsitonina v differentsialnoy diagnostike mikrobno-vospalitelnyih zabolevaniy pochek. Aktualnyie problemyi detskoy nefrologii. Materialyi Mezhdunarodnoy shkolyi i nauchno-prakticheskoy konferentsii po detskoy nefrologii, Orenburg, 2010;130

37. Mantadakis E, Plessa E, Vouloumanou EK, Karageorgopoulos DE, Chatzimichael A. Serum procalcitonin for prediction of renal parenchymal involvement in children with urinary tract infections: a meta-analysis of prospective clinical studies. The Journal of Pediatrics 2009; 155: (6): 875–881

38. Benador N, Siegrist C-A, Gendrel D et al. Procalcitonin is a marker of severity of renal lesions in pyelonephritis. Pediatrics1998; 102:1422–1425

39. Nikfar R, Khotaee G, Ataee N, Shams S. Usefulness of procalcitonin rapid test for the diagnosis of acute pyelonephritis in children in the emergency department. Pediatrics International 2010; 52:(2):196–198

40. Bressan S, Andreola B, Zucchetta P, Montini G. Procaltitonin as a predictor of renal scarring in infants and young children. Pediatr Nephrology 2009; 24: 1199–1204

41. Kotoula A, Gardikis S, Tsalkidis A. Procaltitonin for the early prediction of renal parenchymal involvement in the children with UTI: preliminary results. International Urology and Nephrology 2009; 41 (2):393–399